---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015504"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:59:24.393501+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q2 net loss $32.9M ($0.81 EPS); FDA fast track and ODD for evorpacept

## Summary
- Net loss GAAP $32.9M ($0.81/share) vs $16.3M ($0.40) in Q2 2021; R&D spend $26.7M vs $11.2M.
- Cash/investments $324.2M sufficient to fund operations through Q4 2024.
- FDA granted Fast Track designation for evorpacept in 1st-line PD-L1+ HNSCC; ODD for AML.
- ASPEN-05 (AML) Phase 1 dose escalation completed; enrollment paused for dose optimization pending ASPEN-02 data.
- ASPEN-06 gastric/GEJ Phase 2 results expected 2023; ASPEN-07 (UC) initiation planned Q4 2022.

## SEC filing metadata
- accession: 0000950170-22-015504
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017022015504/0000950170-22-015504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017022015504/alxo-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015504
- JSON: https://secwatch.observer/filing/0000950170-22-015504.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015504.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.